GH Research (GHRS) Cash & Current Investments (2020 - 2026)
GH Research (GHRS) posted quarterly Cash & Current Investments of $246.3 million for Q4 2025, up 104.91% year-over-year from $120.2 million in Q4 2024, and down 1.36% quarter-over-quarter from $249.7 million in Q3 2025.
Analysis
GH Research (GHRS) Cash & Current Investments (2020 - 2026) Analysis & Trends
GH Research's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $246.3 million for Q4 2025.
- In Q4 2025, Cash & Current Investments rose 104.91% year-over-year to $246.3 million; the TTM figure through Dec 2025 stood at $246.3 million (up 104.91% YoY), while the FY2025 annual figure was $246.3 million, up 104.91% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $246.3 million, down from $249.7 million in the prior quarter.
- The five-year high for Cash & Current Investments was $280.7 million in Q3 2021, with the low at $120.2 million in Q4 2024.
- The 5-year median for Cash & Current Investments is $206.1 million (2022), against an average of $200.6 million.
- The sharpest annual moves came in 2021 and 2023: Cash & Current Investments jumped 5535620.0% in 2021, then sank 44.76% in 2023.
- GH Research's Cash & Current Investments stood at $276.8 million in 2021, then tumbled by 40.04% to $166.0 million in 2022, then decreased by 19.23% to $134.0 million in 2023, then slipped by 10.34% to $120.2 million in 2024, then surged by 104.91% to $246.3 million in 2025.
- Business Quant data shows GHRS's Cash & Current Investments at $246.3 million in Q4 2025, $249.7 million in Q3 2025, and $253.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | 362.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 362.65 Mn |
| Mar 31, 2026 | 267.33 Mn |
| Dec 31, 2025 | 280.71 Mn |
| Sep 30, 2025 | 249.65 Mn |
| Jun 30, 2025 | 253.87 Mn |
| Mar 31, 2025 | 257.51 Mn |
| Dec 31, 2024 | 120.18 Mn |
| Sep 30, 2024 | 122.58 Mn |
| Jun 30, 2024 | 129.10 Mn |
| Mar 31, 2024 | 128.83 Mn |
| Dec 31, 2023 | 24.42 Mn |
| Sep 30, 2023 | 141.93 Mn |
| Jun 30, 2023 | 151.62 Mn |
| Mar 31, 2023 | 159.14 Mn |
| Dec 31, 2022 | 165.96 Mn |
| Sep 30, 2022 | 256.94 Mn |
| Jun 30, 2022 | 265.38 Mn |
| Mar 31, 2022 | 270.75 Mn |
| Dec 31, 2021 | 276.78 Mn |
| Sep 30, 2021 | 280.75 Mn |